Top

Published in:

01-04-2023 | Oral Cancer | Review Article

Role of epigenetics in OSCC: an understanding above genetics

Authors: Priyanka P. Vatsa, Yogita Jindal, Janhavi Bhadwalkar, Ambika Chamoli, Vinal Upadhyay, Amit Mandoli

Published in: Medical Oncology | Issue 4/2023

Abstract

Oral cavity cancer is categorized under head and neck cancer that frequently develops from squamous cells hence also known as oral squamous cell carcinoma (OSCC). Although molecular markers for oral cavity cancer are already known, epigenetic signatures for the same haven’t been explored much. Epigenetic and genetic alterations were initially thought to be discrete mechanisms driving the tumour but the whole exome sequencing of various cancers has revealed the interdependency of epigenetics and genetic alterations. The reversible nature of these epigenetic changes makes them an alluring target for cancer therapeutics. The primary epigenetic alterations in cancer include DNA methylation and histone modifications. These alterations are useful for patient early detection and prognostication. This review summarizes the epigenetic perspective to understand the etiology, epigenetic biomarkers, and epi-drugs for better predictive diagnosis and treatment of OSCC.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Montero PH, Patel SG. Cancer of the oral cavity. Surg Oncol Clin N Am. 2015;24(3):491–508. https://doi.org/10.1016/j.soc.2015.03.006.CrossRefPubMedPubMedCentral

Yete S, Saranath D. MicroRNAs in oral cancer: biomarkers with clinical potential. Oral Oncol. 2020;110:105002. https://doi.org/10.1016/j.oraloncology.2020.105002.CrossRefPubMed

Shrestha AD, Vedsted P, Kallestrup P, Neupane D. Prevalence and incidence of oral cancer in low- and middle-income countries: a scoping review. Eur J Cancer Care (Engl). 2020;29(2):1–7. https://doi.org/10.1111/ecc.13207.CrossRef

Chamoli A, Gosavi AS, Shirwadkar UP, et al. Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol. 2021;121:105451. https://doi.org/10.1016/j.oraloncology.2021.105451.CrossRefPubMed

Farsi NJ, Rousseau MC, Schlecht N, et al. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. Carcinogenesis. 2017;38(12):1188–95. https://doi.org/10.1093/carcin/bgx106.CrossRefPubMed

Vanshika S, Preeti A, Sumaira Q, et al. Incidence OF HPV and EBV in oral cancer and their clinico-pathological correlation– a pilot study of 108 cases. J Oral Biol Craniofac Res. 2021;11(2):180–4. https://doi.org/10.1016/j.jobcr.2021.01.007.CrossRefPubMedPubMedCentral

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020. https://doi.org/10.1038/s41572-020-00224-3.CrossRefPubMedPubMedCentral

Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8(9):11884–94.PubMedPubMedCentral

10.

Yang Y, Wang Y. Role of epigenetic regulation in plasticity of tumor immune microenvironment. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.640369.CrossRefPubMedPubMedCentral

11.

Sim YC, Hwang JH, Ahn KM. Overall and disease-specific survival outcomes following primary surgery for oral squamous cell carcinoma: analysis of consecutive 67 patients. J Korean Assoc Oral Maxillofac Surg. 2019;45(2):83–90. https://doi.org/10.5125/jkaoms.2019.45.2.83.CrossRefPubMedPubMedCentral

12.

Irimie AI, Ciocan C, Gulei D, et al. Current insights into oral cancer epigenetics. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19030670.CrossRefPubMedPubMedCentral

13.

Castilho RM, Squarize CH, Almeida LO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18071506.CrossRefPubMedPubMedCentral

14.

Demetriadou C, Koufaris C, Kirmizis A. Histone N-alpha terminal modifications: genome regulation at the tip of the tail. Epigenetics Chromatin. 2020;13(1):29. https://doi.org/10.1186/s13072-020-00352-w.CrossRefPubMedPubMedCentral

15.

Jones PA, Issa J, pierre J, Baylin S. Targeting the cancer epigenome for therapy. Nat Publ Group. 2016;17(10):630–41. https://doi.org/10.1038/nrg.2016.93.CrossRef

16.

Romanowska K, Sobecka A, Rawłuszko-Wieczorek AA, Suchorska WM, Golusiński W. Head and neck squamous cell carcinoma: epigenetic landscape. Diagnostics (Basel). 2020;11(1):34. https://doi.org/10.3390/diagnostics11010034.CrossRefPubMed

17.

Martin D, Abba MC, Molinolo AA, et al. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget. 2014;5(19):8906–23. https://doi.org/10.18632/oncotarget.2417.CrossRefPubMedPubMedCentral

18.

Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019;3(1):7. https://doi.org/10.1038/s41698-019-0079-0.CrossRefPubMedPubMedCentral

19.

Seo JY, Park YJ, Yi YA, et al. Epigenetics: general characteristics and implications for oral health. Restor Dent Endod. 2015;40(1):14–22. https://doi.org/10.5395/rde.2015.40.1.14.CrossRefPubMed

20.

Wallace EVB, Stoddart D, Heron AJ, et al. Identification of epigenetic DNA modifications with a protein nanopore. Chem Commun (Camb). 2010;46(43):8195–7. https://doi.org/10.1039/c0cc02864a.CrossRefPubMed

21.

Caiafa P, Zampieri M. DNA methylation and chromatin structure: the puzzling CpG islands. J Cell Biochem. 2005;94(2):257–65. https://doi.org/10.1002/jcb.20325.CrossRefPubMed

22.

Krishnan NM, Dhas K, Nair J, et al. A minimal DNA methylation signature in oral tongue squamous cell carcinoma links altered methylation with tumor attributes. Mol Cancer Res. 2016;14(9):805–19. https://doi.org/10.1158/1541-7786.MCR-15-0395.CrossRefPubMed

23.

Dumache R, Rogobete AF, Andreescu N, Puiu M. Genetic and epigenetic biomarkers of molecular alterations in oral carcinogenesis. Clin Lab. 2015;61(10):1373–81. https://doi.org/10.7754/clin.lab.2015.150327.CrossRefPubMed

24.

Das D, Ghosh S, Maitra A, et al. Epigenomic dysregulation-mediated alterations of key biological pathways and tumor immune evasion are hallmarks of gingivo-buccal oral cancer. Clin Epigenetics. 2019;11(1):178. https://doi.org/10.1186/s13148-019-0782-2.CrossRefPubMedPubMedCentral

25.

Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019. https://doi.org/10.1038/s41392-019-0095-0.CrossRefPubMedPubMedCentral

26.

Mascolo M, Siano M, Ilardi G, et al. Epigenetic disregulation in oral cancer. Int J Mol Sci. 2012. https://doi.org/10.3390/ijms13022331.CrossRefPubMedPubMedCentral

27.

Boscolo-Rizzo P, Furlan C, Lupato V, Polesel J, Fratta E. Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin Epigenetics. 2017;9:124. https://doi.org/10.1186/s13148-017-0424-5.CrossRefPubMedPubMedCentral

28.

Gasche JA, Goel A. Epigenetic mechanisms in oral carcinogenesis. Future Oncol. 2012;8(11):1407–25. https://doi.org/10.2217/fon.12.138.CrossRefPubMed

29.

Al-Kaabi A, van Bockel LW, Pothen AJ, Willems SM. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review. Dis Markers. 2014. https://doi.org/10.1155/2014/260549.CrossRefPubMedPubMedCentral

30.

Bhatia V, Goel MM, Makker A, et al. Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma. Biomed Res Int. 2014. https://doi.org/10.1155/2014/248419.CrossRefPubMedPubMedCentral

31.

Kim SY, Han YK, Song JM, et al. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC). Clin Epigenetics. 2019;11(1):116. https://doi.org/10.1186/s13148-019-0715-0.CrossRefPubMedPubMedCentral

32.

Liyanage C, Wathupola A, Muraleetharan S, Perera K, Punyadeera C, Udagama P. Promoter hypermethylation of tumor-suppressor genes p16(INK4a), RASSF1A, TIMP3, and PCQAP/MED15 in salivary DNA as a quadruple biomarker panel for early detection of oral and oropharyngeal cancers. Biomolecules. 2019. https://doi.org/10.3390/biom9040148.CrossRefPubMedPubMedCentral

33.

Viet CT, Jordan RCK, Schmidt BL. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. J Calif Dent Assoc. 2007;35(12):844–9.PubMed

34.

Misawa K, Imai A, Mochizuki D, et al. Association of TET3 epigenetic inactivation with head and neck cancer. Oncotarget. 2018;9(36):24480–93. https://doi.org/10.18632/oncotarget.25333.CrossRefPubMedPubMedCentral

35.

Basu B, Chakraborty J, Chandra A, et al. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India. Clin Epigenetics. 2017;9(1):1–15. https://doi.org/10.1186/s13148-017-0314-x.CrossRef

36.

Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713. https://doi.org/10.1101/cshperspect.a018713.CrossRefPubMedPubMedCentral

37.

Chang CC, Lin BR, Chen ST, Hsieh TH, Li YJ, Kuo MYP. HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma. J Oral Pathol Med. 2011;40(7):567–75. https://doi.org/10.1111/j.1600-0714.2011.01009.x.CrossRefPubMed

38.

D’Souza W, Saranath D. Clinical implications of epigenetic regulation in oral cancer. Oral Oncol. 2015;51(12):1061–8. https://doi.org/10.1016/j.oraloncology.2015.09.006.CrossRefPubMed

39.

Webber LP, Wagner VP, Curra M, et al. Hypoacetylation of acetyl-histone H3 (H3K9ac) as marker of poor prognosis in oral cancer. Histopathology. 2017;71(2):278–86. https://doi.org/10.1111/his.13218.CrossRefPubMed

40.

Sakuma T, Uzawa K, Onda T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 2006;29(1):117–24.PubMed

41.

Yang H, Jin X, Dan H, Chen Q. Histone modifications in oral squamous cell carcinoma and oral potentially malignant disorders. Oral Dis. 2020;26(4):719–32.CrossRefPubMed

42.

Le JM, Squarize CH, Castilho RM. Histone modifications: targeting head and neck cancer stem cells. World J Stem Cells. 2014;6(5):511–25. https://doi.org/10.4252/wjsc.v6.i5.511.CrossRefPubMedPubMedCentral

43.

Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20(1):245. https://doi.org/10.1186/s13059-019-1870-5.CrossRefPubMedPubMedCentral

44.

Gaździcka J, Gołąbek K, Strzelczyk JK, Ostrowska Z. Epigenetic modifications in head and neck cancer. Biochem Genet. 2020;58(2):213–44. https://doi.org/10.1007/s10528-019-09941-1.CrossRefPubMed

45.

Špilak A, Brachner A, Kegler U, Neuhaus W, Noehammer C. Implications and pitfalls for cancer diagnostics exploiting extracellular vesicles. Adv Drug Deliv Rev. 2021;175:113819. https://doi.org/10.1016/j.addr.2021.05.029.CrossRefPubMed

46.

Arantes LMRB, de Carvalho AC, Melendez ME, et al. Validation of methylation markers for diagnosis of oral cavity cancer. Eur J Cancer. 2015;51(5):632–41. https://doi.org/10.1016/j.ejca.2015.01.060.CrossRefPubMed

47.

Cristaldi M, Mauceri R, di Fede O, Giuliana G, Campisi G, Panzarella V. Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: current status and perspectives. Front Physiol. 2019;10:1476. https://doi.org/10.3389/fphys.2019.01476.CrossRefPubMedPubMedCentral

48.

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016. https://doi.org/10.1101/cshperspect.a019505.CrossRefPubMedPubMedCentral

49.

Kusumoto T, Hamada T, Yamada N, et al. Comprehensive epigenetic analysis using oral rinse samples: A pilot study. J Oral Maxillofac Surg. 2012;70(6):1486–94. https://doi.org/10.1016/j.joms.2011.04.021.CrossRefPubMed

50.

Ferlazzo N, Currò M, Zinellu A, et al. Influence of MTHFR genetic background on p16 and MGMT methylation in oral squamous cell cancer. Int J Mol Sci. 2017;18(4):1–10. https://doi.org/10.3390/ijms18040724.CrossRef

51.

Nagata S, et al. Aberrant DNA methylation of tumor-related genes in oral rinse. Cancer. 2012. https://doi.org/10.1002/cncr.27417.CrossRefPubMedPubMedCentral

52.

Surgery M, Unit MS. Analysis of salivary detection of P16INK4A and RASSF1A promoter gene methylation and its association with oral squamous cell carcinoma in a Colombian population. J Clin Exp. 2020. https://doi.org/10.4317/jced.56647.CrossRef

53.

Jaffe A. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res. 2011. https://doi.org/10.1158/1940-6207.CAPR-11-0006.CrossRef

54.

Liu Y, He Z, tong ZQ bo. DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients. Med Oncol. 2012. https://doi.org/10.1007/s12032-011-9953-5.CrossRefPubMedPubMedCentral

55.

Cheng SJ, Chang CF, Ko HH, et al. Hypermethylated ZNF582 and PAX1 genes in mouth rinse samples as biomarkers for oral dysplasia and oral cancer detection. Head Neck. 2018;40(2):355–68. https://doi.org/10.1002/hed.24958.CrossRefPubMed

56.

Sun Y, wan, Chen K Ming, Kawasawa YI, et al. Hypomethylated Fgf3 is a potential biomarker for early detection of oral cancer in mice treated with the tobacco carcinogen dibenzo [def, p ] chrysene. PLoS ONE. 2017. https://doi.org/10.1371/journal.pone.0186873.CrossRefPubMedPubMedCentral

57.

Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res. 2007;13(4):1179–85. https://doi.org/10.1158/1078-0432.CCR-06-2027.CrossRefPubMed

58.

Rapado-González Ó, López-Cedrún JL, López-López R, Rodríguez-Ces AM, Suárez-Cunqueiro MM. Saliva gene promoter hypermethylation as a biomarker in oral cancer. J Clin Med. 2021. https://doi.org/10.3390/jcm10091931.CrossRefPubMedPubMedCentral

59.

Kaliyaperumal S, Sankarapandian S. Evaluation of p16 hypermethylation in oral submucous fibrosis: a quantitative and comparative analysis in buccal cells and saliva using real-time methylation-specific polymerase chain reaction. South Asian J Cancer. 2016;5(2):73–9. https://doi.org/10.4103/2278-330X.181645.CrossRefPubMedPubMedCentral

60.

Yang Y, Lu T, Li Z, Lu S. FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer. Cell Adh Migr. 2020;14(1):82–95. https://doi.org/10.1080/19336918.2020.1766308.CrossRefPubMedPubMedCentral

61.

Dubot C, Bernard V, Sablin MP, et al. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals <em>FGFR1</em> amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. Eur J Cancer. 2018;91:47–55. https://doi.org/10.1016/j.ejca.2017.12.016.CrossRefPubMed

62.

Bogatyrova O, Mattsson JSM, Ross EM, et al. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. Eur J Cancer. 2021;151:136–49. https://doi.org/10.1016/j.ejca.2021.04.005.CrossRefPubMed

63.

Ribeiro IP, Caramelo F, Esteves L, et al. Genomic and epigenetic signatures associated with survival rate in oral squamous cell carcinoma patients. J Cancer. 2018;9(11):1885–95. https://doi.org/10.7150/jca.23239.CrossRefPubMedPubMedCentral

64.

Meng RW, Li YC, Chen X, et al. Aberrant methylation of RASSF1A closely associated with HNSCC, a meta-analysis. Sci Rep. 2016;6:20756. https://doi.org/10.1038/srep20756.CrossRefPubMedPubMedCentral

65.

Wen G, Wang H, Zhong Z. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: a PRISMA-compliant meta-analysis. Medicine. 2018;97(11):e9971.CrossRefPubMedPubMedCentral

66.

Wu Y, Hu H, Zhang W, et al. SUZ12 is a novel putative oncogene promoting tumorigenesis in head and neck squamous cell carcinoma. J Cell Mol Med. 2018;22(7):3582–94. https://doi.org/10.1111/jcmm.13638.CrossRefPubMedPubMedCentral

67.

Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018;6(1):10. https://doi.org/10.1186/s40364-018-0122-2.CrossRefPubMedPubMedCentral

68.

li Z, Wang Y, Qiu J, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013;4(12):2532.CrossRef

69.

Guerrero-Preston R, Soudry E, Acero J, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila). 2011;4(7):1061–72. https://doi.org/10.1158/1940-6207.CAPR-11-0006.CrossRefPubMed

70.

Xie SL, Fan S, Zhang SY, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. 2018;142(6):1252–65. https://doi.org/10.1002/ijc.31134.CrossRefPubMed

71.

You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9–20. https://doi.org/10.1016/j.ccr.2012.06.008.CrossRefPubMedPubMedCentral

72.

Shih CH, Chang YJ, Huang WC, et al. EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis. Oncogene. 2017;36(47):6542–54. https://doi.org/10.1038/onc.2017.262.CrossRefPubMedPubMedCentral

73.

Shilpi G, Prabhat K, Jayant M, Harsimrut K, Bhudev C, das. Epigenetic biomarkers in head and neck cancer. J Cancer Genetics Biomarkers. 2018;1(2):41–50. https://doi.org/10.14302/issn.2572-3030.jcgb-18-2428.CrossRef

74.

Bhadury J, Nilsson LM, Veppil S, Green LC, Li Z, Gesner EM. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA. 2014. https://doi.org/10.1073/pnas.1406722111.CrossRefPubMedPubMedCentral

75.

Dennis MK, Field AS, Burai R, et al. Efficacy of azacitadine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001). Lancet Oncol. 2012;127(3):358–66. https://doi.org/10.1016/S1470-2045(09)70003-8.CrossRef

76.

Yang X, Han H, de Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577–90. https://doi.org/10.1016/j.ccr.2014.07.028.CrossRefPubMedPubMedCentral

77.

Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15(11):3881–8. https://doi.org/10.1158/1078-0432.CCR-08-2196.CrossRefPubMed

78.

Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383(7):650–63. https://doi.org/10.1056/nejmra1805035.CrossRefPubMed

79.

Wong KK, Hassan R, Yaacob NS. Hypomethylating agents and immunotherapy: therapeutic synergism in acute myeloid leukemia and myelodysplastic syndromes. Front Oncol. 2021;11:1–16. https://doi.org/10.3389/fonc.2021.624742.CrossRef

80.

Issa JPJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16(9):1099–110. https://doi.org/10.1016/S1470-2045(15)00038-8.CrossRefPubMedPubMedCentral

81.

Okabe A, Huang KK, A., Huang, K. K., Matsusaka, K., Fukuyo, M., Xing, M., Ong, X., Hoshii, T., Usui, G., Seki, M., Mano, Y., Rahmutulla, B., Kanda, T., Suzuki, T., Rha, S. Y., Ushiku, T., Fukayama, M., Tan, P., & Kaneda, A. Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus–positive gastric adenocarcinoma. Nat Genet. 2020;52(9):919–30. https://doi.org/10.1038/s41588-020-0665-7.CrossRefPubMed

82.

Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol. 2007;31(6):1449–56. https://doi.org/10.3892/ijo.31.6.1449.CrossRefPubMed

83.

Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by Zebularine. J Natl Cancer Inst. 2003;95(5):399–409. https://doi.org/10.1093/jnci/95.5.399.CrossRefPubMed

84.

Bhol CS, Mishra SR, Patil S, et al. (2022) PAX9 reactivation by inhibiting DNA methyltransferase triggers antitumor effect in oral squamous cell carcinoma. Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease. 1868;9:166428. https://doi.org/10.1016/j.bbadis.2022.166428.CrossRef

85.

Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise. Nat Rev Clin Oncol. 2020;17(2):91–107. https://doi.org/10.1038/s41571-019-0267-4.CrossRefPubMed

86.

Gama RR, Arantes LMRB, Sorroche BP, et al. Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid. Sci Rep. 2021;11(1):16415. https://doi.org/10.1038/s41598-021-95845-3.CrossRefPubMedPubMedCentral

87.

West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30–9. https://doi.org/10.1172/JCI69738.CrossRefPubMedPubMedCentral

88.

Ma J, Guo X, Zhang S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines. Mol Med Rep. 2015;11(6):4525–31. https://doi.org/10.3892/mmr.2015.3268.CrossRefPubMed

89.

Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060–6. https://doi.org/10.1182/blood-2007-06-098061.CrossRefPubMed

90.

Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol. 2007;30(5):1181–8. https://doi.org/10.3892/ijo.30.5.1181.CrossRefPubMed

91.

Sang Z, Sun Y, Ruan H, Cheng Y, Ding X, Yu Y. Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro. Exp Ther Med. 2016;12(6):3979–87. https://doi.org/10.3892/etm.2016.3907.CrossRefPubMedPubMedCentral

92.

Marques AEM, do Nascimento Filho CH v, Marinho Bezerra TM, Guerra ENS, Castilho RM, Squarize CH. Entinostat is a novel therapeutic agent to treat oral squamous cell carcinoma. J Oral Pathol Med. 2020;49(8):771–9. https://doi.org/10.1111/jop.13039.CrossRefPubMed

93.

Mochizuki D, Misawa Y, Kawasaki H, et al. Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation. Int J Mol Sci. 2018;19(12):1–13. https://doi.org/10.3390/ijms19123707.CrossRef

94.

de Guillebon E, Jimenez M, Mazzarella L, et al. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. ESMO Open. 2021;6(3):100106. https://doi.org/10.1016/j.esmoop.2021.100106.CrossRefPubMedPubMedCentral

95.

Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494–507. https://doi.org/10.1038/s41571-019-0190-8.CrossRefPubMedPubMedCentral

96.

Lima DG, do Amaral GCLS, Planello AC, Borgato GB, Guimarães GN, de Souza AP. Combined therapy with cisplatin and 5-AZA-2CdR modifies methylation and expression of DNA repair genes in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2022;15(3):131–44.PubMedPubMedCentral

97.

Huang Z, Zhang Y, Li H, et al. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-κB pathway activation through RPS3. Cell Death Dis. 2019;10(12):936. https://doi.org/10.1038/s41419-019-2177-x.CrossRefPubMedPubMedCentral

98.

Bruzzese F, Leone A, Rocco M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 2011;226(9):2378–90. https://doi.org/10.1002/jcp.22574.CrossRefPubMed

99.

Caponigro F, di Gennaro E, Ionna F, et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer. 2016;16(1):1–10. https://doi.org/10.1186/s12885-016-2957-y.CrossRef

100.

Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24. https://doi.org/10.1093/intimm/dxm057.CrossRefPubMed

101.

Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73(6):1733–41. https://doi.org/10.1158/0008-5472.CAN-12-2384.CrossRefPubMedPubMedCentral

102.

Bais M, v. Impact of epigenetic regulation on head and neck squamous cell carcinoma. J Dent Res. 2019;98(3):268–76. https://doi.org/10.1177/0022034518816947.CrossRefPubMedPubMedCentral

103.

Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156. https://doi.org/10.1186/s13045-021-01164-5.CrossRefPubMedPubMedCentral

104.

Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents Anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26(1):290–300. https://doi.org/10.1158/1078-0432.CCR-19-1351.CrossRefPubMed

Title: Role of epigenetics in OSCC: an understanding above genetics
Authors: Priyanka P. Vatsa
Yogita Jindal
Janhavi Bhadwalkar
Ambika Chamoli
Vinal Upadhyay
Amit Mandoli
Publication date: 01-04-2023
Publisher: Springer US
Keywords: Oral Cancer
Epigenetics
Oral Cavity Carcinoma
Published in: Medical Oncology / Issue 4/2023
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-01992-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors

Investigation of the effect of rhamnetin on mice injected with solid and ehrlich ascites tumor

Phospho PTEN mediated dephosphorylation of mitotic kinase PLK1 and Aurora Kinase A prevents aneuploidy and preserves genomic stability

Adjuvant treatment of surgically treated bone metastasis patients: association with hospital characteristics and trends over time

In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer

Nutrition care is an integral part of patient-centred medical care: a European consensus

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage